Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Praxis Precision Medicines (PRAX)
NASDAQ:PRAX
RESEARCH TOOLSreports
Praxis Precision Medicines (PRAX) Stock Price & Analysis
478 Followers
PRAX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.76 - $67.21
Previous Close$54.96
Volume318.81K
Average Volume (3M)375.16K
Market Cap
$940.25M
Enterprise Value$735.06M
Total Cash (Recent Filing)$207.42M
Total Debt (Recent Filing)$2.22M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Aug 06, 2024EPS Estimate
-$2.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.91
Shares Outstanding17,107,887
10 Day Avg. Volume456,636
30 Day Avg. Volume375,159
Standard Deviation0.35
R-Squared0.16
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)3.11
Price to Sales (P/S)291.54
Price to Cash Flow (P/CF)-8.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue334.88
Enterprise Value/Gross Profit300.39
Enterprise Value/Ebitda-5.92
Forecast
1Y Price Target
$155.50Price Target Upside182.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Praxis Precision Medicines News
PremiumCompany Announcements
Praxis Precision Medicines Shapes Future with Key Elections and ApprovalsBulls Say, Bears Say
Bulls Say
Competitive AdvantageCompetitive landscape for PRAX in essential tremor has been meaningfully improved with this setback to PRAX's closest competitor in this space.
Financial StabilityPraxis has a cash runway into 2027 and an early pipeline across the Cerebrum and Solidus platforms, with potential to generate significant long-term value.
Product PotentialSales of its lead product Ulixa for essential tremor (ET), if successful in Ph 3, could peak at over $1B.
Bears Say
Clinical TrialsConcerns are growing about the probability of success for PRAX's ongoing phase 3 trial of ulixacaltamide in essential tremor.
EarningsPRAX traded down after announcing earnings, likely due to higher-than-expected expenses.
Investor SentimentInvestor sentiment is mixed-to-negative regarding the success of PRAX's phase 3 trial for ulixacaltamide in treating essential tremor.
---
Ownership Overview
Currently, No data available
---
PRAX FAQ
What was Praxis Precision Medicines’s price range in the past 12 months?
Praxis Precision Medicines lowest stock price was $12.76 and its highest was $67.21 in the past 12 months.
What is Praxis Precision Medicines’s market cap?
Currently, no data Available
When is Praxis Precision Medicines’s upcoming earnings report date?
Praxis Precision Medicines’s upcoming earnings report date is Aug 06, 2024 which is in 15 days.
How were Praxis Precision Medicines’s earnings last quarter?
Praxis Precision Medicines released its earnings results on May 12, 2024. The company reported -$2.84 earnings per share for the quarter, missing the consensus estimate of -$2.083 by -$0.757.
Is Praxis Precision Medicines overvalued?
According to Wall Street analysts Praxis Precision Medicines’s price is currently Undervalued.
Does Praxis Precision Medicines pay dividends?
Praxis Precision Medicines does not currently pay dividends.
What is Praxis Precision Medicines’s EPS estimate?
Praxis Precision Medicines’s EPS estimate is -$2.31.
How many shares outstanding does Praxis Precision Medicines have?
Praxis Precision Medicines has 17,107,887 shares outstanding.
What happened to Praxis Precision Medicines’s price movement after its last earnings report?
Praxis Precision Medicines reported an EPS of -$2.84 in its last earnings report, missing expectations of -$2.083. Following the earnings report the stock price went down -1.883%.
Which hedge fund is a major shareholder of Praxis Precision Medicines?
Among the largest hedge funds holding Praxis Precision Medicines’s share is RA Capital Management. It holds Praxis Precision Medicines’s shares valued at 51M.
---
Praxis Precision Medicines Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$155.50 (182.93% Upside)
$155.50 (182.93% Upside)
Blogger Sentiment
Bullish
PRAX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
218.60%
12-Months-Change
Fundamentals
Return on Equity
-85.25%
Trailing 12-Months
Asset Growth
154.52%
Trailing 12-Months
Company Description
Praxis Precision Medicines
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in developing therapies for patients and families affected by complex and debilitating brain disorders. The firm's pipeline covers PRAX-114, PRAX-944, PRAX-562, and PRAX-222 among others.
---
PRAX Stock 12 Month Forecast
Average Price Target
$155.50
▲(182.93% Upside)
Technical Analysis
Best Analysts Covering PRAX
1 Year
1 Year Success Rate
13/22 ratings generated profit
1 Year Average Return
+69.12%
reiterated a buy rating 2 months ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 59.09% of your transactions generating a profit, with an average return of +69.12% per trade.
---